TP53 and ameloblastoma: The study of Bartels et al. assessed BRAF wild-type ameloblastomas by targeted NGS and identified FGFR2 mutations in 4/7 (57%) of them, including one FGFR2/TP53/PTEN-triple-mutant case [72].